B.Riley analyst Mayank Mamtani reiterated a Buy rating and $6.00 price target on Trevi Therapeutics (NASDAQ: TRVI).The analyst comments "On ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE